[DOI] [PMC free article] [PubMed] [Google Scholar] Chouchani ET, Kazak L, Jedrychowski MP, Lu GZ, Erickson BK, Szpyt J, Pierce KA, Laznik-Bogoslavski D, Vetrivelan R, Clish CB, et al
This give a comparison to how the various peptides compare to GH for increasing IGF-1
Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, et al
Clinical studies show Tesamorelin peptide therapy reduces visceral belly fat by 15 to 18 percent and it works specifically on the deep abdominal fat that diet and exercise cannot reach
However, preclinical safety studies report no major toxicity across animal studies (mice, rats, rabbits, dogs) and showed no adverse effects across several organ systems